Product Description
Luvadaxistat (also known as TAK-831; NBI-1065844), an inhibitor of the enzyme d-amino acid oxidase, has demonstrated beneficial effects in preclinical models relevant to FRDA.Ê Friedreich ataxia (FRDA) is a rare disorder with progressive neurodegeneration and cardiomyopathy. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34018342/)
Mechanisms of Action: DAAO Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Neurocrine
Company Location: SAN DIEGO CA 92130
Company CEO: Kevin C. Gorman
Additional Commercial Interests: Takeda
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ERUDITE Study | P2 |
Active, not recruiting |
Schizophrenia |
2026-02-10 |